the case for the use of pparγ agonists as an adjunctive therapy for cerebral malaria的pparγ受体激动剂的使用作为一种辅助治疗脑型疟疾.pdfVIP

Hindawi Publishing Corporation PPAR Research Volume 2012, Article ID 513865, 12 pages doi:10.1155/2012/513865 Review Article The Case for the Use of PPARγ Agonists as an Adjunctive Therapy for Cerebral Malaria Lena Serghides Sandra A. Rotman Laboratories, McLaughlin-Rotman Centre for Global Health, Toronto General Hospital, University Health Network, 101 College Street, Suite 10-359, Toronto, ON, Canada M5G 1L7 Correspondence should be addressed to Lena Serghides, lena.serghides@utoronto.ca Received 7 January 2011; Accepted 28 February 2011 Academic Editor: Marion M. Chan Copyright © 2012 Lena Serghides. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Cerebral malaria is a severe complication of Plasmodium falciparum infection associated with high mortality even when highly effective antiparasitic therapy is used. Adjunctive therapies that modify the pathophysiological processes caused by malaria are a possible way to improve outcome. This review focuses on the utility of PPARγ agonists as an adjunctive therapy for the treatment of cerebral malaria. The current knowledge of PPARγ agonist use in malaria is summarized. Findings from experimental CNS injury and disease models that demonstrate the potential for PPARγ agonists as an adjunctive therapy for cerebral malaria are also discussed. 1. Introduction Intravenous artesunate is now the standard of care for severe malaria in both adults and children following Few diseases have the global health and economic i